Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study
{{output}}
Background: To date, no post-marketing safety studies of satralizumab have been conducted. This study aims to evaluate the post-marketing safety profile of satralizumab using data from the U.S. Food and Drug Administration (FDA) ... ...
